Guillain-Barré二氏症候群市場規模、佔有率和成長分析：按療法、GBS亞型、給藥途徑、分銷管道、患者年齡層、最終用戶和地區分類－2026-2033年產業預測

2024 年全球Guillain-Barré二氏症候群市場價值為 6.0593 億美元，預計到 2033 年將從 2025 年的 6.4289 億美元成長至 10.3243 億美元，預測期（2026-2033 年）的複合年成長率為 6.1%。

受病毒爆發導致自體免疫神經病變盛行率上升以及人口老化等因素的推動，全球Guillain-Barré二氏症候群(GBS) 市場正經歷顯著成長。該市場的關鍵組成部分包括診斷試劑盒、靜脈注射免疫球蛋白 (IVIG) 療法以及對及時治療患者至關重要的創新血漿置換技術。大規模病毒爆發後，可擴展治療方案的重要性促使生產能力加強。此外，美國和歐洲衛生當局對 GBS 監測的投入正在加速研發，從而推動更多臨床試驗和生物製藥的上市。不斷變化的保險報銷體係以及神經科對早期療育意識的提高正在改變醫療實踐。人工智慧在診斷中的應用正在提高模式識別和治療效率，最終實現更快、更有效的患者康復，同時也增強了 GBS 市場相關人員的信心。

全球Guillain-Barré二氏症候群市場的成長要素

公眾和醫療專業人員對Guillain-Barré二氏症候群的認知不斷提高，對於促進症狀的早期發現至關重要，使患者能夠更快地接受醫療評估。早期診斷能夠確保患者及時獲得成熟的治療方案，從而改善臨床療效，並鼓勵醫療機構採用新的治療方案。這種認知的提高也推動了宣傳宣傳活動和支持活動的發展，使更多患者能夠利用醫療服務。因此，對診斷服務、治療性介入和支持性護理的需求不斷成長，推動了全球醫療保健市場的持續發展。

全球Guillain-Barré二氏症候群市場的限制因素

全球Guillain-Barré二氏症候群市場面臨許多重大限制因素，尤其是在醫療基礎設施往往不足的開發中國家和偏遠地區。缺乏專業的神經科醫療服務會阻礙對該疾病的準確診斷和有效治療。此外，訓練有素的醫護人員短缺和診斷設備有限會導致治療啟動延遲，造成病例漏報和現有治療手段利用率降低。地理因素進一步阻礙了患者獲得治療，迫使他們依賴不完全的基層醫療服務。這些系統性問題最終會阻礙市場成長，並限制服務不足地區對先進治療及相關支援服務的需求。

Guillain-Barré二氏症候群的全球市場趨勢

受標靶免疫調節劑進展的推動，全球Guillain-Barré二氏症候群市場正顯著轉向個人化免疫療法。醫療服務提供者致力於在改善患者復健效果的同時，最大限度地減少全身性副作用，因此越來越重視根據個別患者的具體情況客製化免疫抑制方案。生物標記的發現和適應性臨床試驗設計的創新推動了這一趨勢，促進了生物技術公司與專業醫療機構之間的合作。因此，拓展開發平臺，轉向精準醫療方法變得日益重要，這反映了該疾病管理領域在全球範圍內的範式轉變，即優先考慮個人化療法。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球Guillain-Barré二氏症候群市場規模：依治療方法分類

• 靜脈注射免疫球蛋白（IVIG）
• 血漿置換（血漿分離術）
• 補體抑制劑（新興）
• 其他藥物治療

全球Guillain-Barré二氏症候群市場規模：依GBS亞型分類

• 急性發炎性去髓鞘化多發性神經病變（AIDP）
• 急性運動軸索性神經病變（AMAN）
• 急性運動感覺軸索性神經病變（AMSAN）
• 其他亞型

全球Guillain-Barré二氏症候群市場規模：依給藥途徑分類

• 靜脈
• 皮下

Guillain-Barré二氏症候群全球市場規模：按分銷管道分類

• 醫院藥房
• 家庭靜脈輸液服務提供者
• 零售藥房

全球Guillain-Barré二氏症候群市場規模：依患者年齡層分類

• 兒童
• 成年人（18-64歲）
• 老年人（65歲以上）

全球Guillain-Barré二氏症候群市場規模：依最終用戶分類

• 醫院
• 門診部

全球Guillain-Barré二氏症候群市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• CSL Behring LLC
• Grifols SA
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Kedrion Biopharma Inc.
• Biotest AG
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• AbbVie Inc.
• Novartis AG
• Chugai Pharmaceutical Co., Ltd.
• Argenx SE
• Alnylam Pharmaceuticals, Inc.
• Annexon Biosciences Inc.
• Hansa Medical AB
• Akari Therapeutics PLC
• Alexion Pharmaceuticals Inc.（AstraZeneca）
• Cadila Healthcare Limited（Zydus）
• Biogen Inc.
• Sarepta Therapeutics, Inc.

結論與建議

Global Guillain Barre Syndrome Market size was valued at USD 605.93 Million in 2024 and is poised to grow from USD 642.89 Million in 2025 to USD 1032.43 Million by 2033, growing at a CAGR of 6.1% during the forecast period (2026-2033).

The global Guillain-Barre syndrome (GBS) market is experiencing significant growth, driven by the increasing prevalence of autoimmune neuropathies, influenced by viral outbreaks and aging demographics. Key market components include diagnostic kits, intravenous immunoglobulin (IVIG) therapies, and innovative plasma-exchange technologies essential for timely patient care. The importance of scalable therapeutic options has prompted heightened production efforts following notable viral events. Furthermore, U.S. and European health agencies are investing in GBS monitoring, stimulating research and development, which accelerates clinical trials and market access for biologics. The evolution of the reimbursement landscape and increased neurologist awareness regarding early interventions are reshaping care practices. AI's role in diagnostics enhances pattern recognition and treatment efficiency, ultimately facilitating faster and more effective patient outcomes while fostering confidence among stakeholders in the GBS market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Guillain Barre Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Guillain Barre Syndrome Market Segments Analysis

Global guillain barre syndrome market is segmented by therapeutics, gbs variant, route of administration, distribution channel, patient age group, end user and region. Based on therapeutics, the market is segmented into Intravenous Immunoglobulin (IVIG), Plasma Exchange (Plasmapheresis), Complement Inhibitors (Emerging) and Other Pharmacological Treatments. Based on gbs variant, the market is segmented into Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Acute Motor Axonal Neuropathy (AMAN), Acute Motor and Sensory Axonal Neuropathy (AMSAN) and Other Variants. Based on route of administration, the market is segmented into Intravenous and Subcutaneous. Based on distribution channel, the market is segmented into Hospital Pharmacies, Home Infusion Providers and Retail Pharmacies. Based on patient age group, the market is segmented into Pediatric, Adult (18-64) and Geriatric (65+). Based on end user, the market is segmented into Hospitals and Ambulatory Care Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Guillain Barre Syndrome Market

The increasing awareness among both the public and healthcare professionals regarding Guillain-Barre syndrome plays a crucial role in enhancing the early recognition of symptoms, leading patients to pursue medical evaluation more promptly. Such early diagnoses facilitate timely access to established treatments, resulting in improved clinical outcomes and encouraging healthcare providers to integrate new treatment protocols. This surge in awareness also fuels educational campaigns and advocacy efforts, which help broaden the patient demographic that engages with healthcare services. As a result, there is a growing demand for diagnostic services, therapeutic interventions, and supportive care options, which in turn drives ongoing market growth in the global healthcare landscape.

Restraints in the Global Guillain Barre Syndrome Market

The global market for Guillain-Barre syndrome faces several significant constraints, particularly in developing and remote areas where healthcare infrastructure is often inadequate. The absence of specialized neurologic services can impede accurate diagnosis and effective management of the condition. Additionally, a shortage of trained healthcare professionals and limited access to diagnostic equipment delay the initiation of treatment, resulting in under-reporting of cases and lower utilization of available therapies. Geographic challenges further complicate access, forcing patients to depend on insufficient primary care. These systemic issues ultimately hinder market growth, limiting demand for advanced treatments and related support services in underserved populations.

Market Trends of the Global Guillain Barre Syndrome Market

The Global Guillain-Barre Syndrome market is witnessing a notable trend toward personalized immunotherapy solutions, driven by advancements in targeted immunomodulatory agents. The focus on tailoring immune suppression to individual patient profiles is gaining traction as healthcare providers aim to enhance recovery outcomes while minimizing systemic side effects. This trend is bolstered by innovations in biomarker identification and adaptive trial designs, which encourage collaboration between biotech firms and specialized healthcare institutions. Consequently, there is a growing emphasis on expanding research and development pipelines for precision medicine approaches, reflecting a shift in treatment paradigms that prioritize personalized regimens in the management of this condition on a global scale.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Guillain Barre Syndrome Market Size by Therapeutics & CAGR (2026-2033)

• Market Overview
• Intravenous Immunoglobulin (IVIG)
• Plasma Exchange (Plasmapheresis)
• Complement Inhibitors (Emerging)
• Other Pharmacological Treatments

Global Guillain Barre Syndrome Market Size by GBS Variant & CAGR (2026-2033)

• Market Overview
• Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
• Acute Motor Axonal Neuropathy (AMAN)
• Acute Motor and Sensory Axonal Neuropathy (AMSAN)
• Other Variants

Global Guillain Barre Syndrome Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Subcutaneous

Global Guillain Barre Syndrome Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Home Infusion Providers
• Retail Pharmacies

Global Guillain Barre Syndrome Market Size by Patient Age Group & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult (18-64)
• Geriatric (65+)

Global Guillain Barre Syndrome Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ambulatory Care Centers

Global Guillain Barre Syndrome Market Size & CAGR (2026-2033)

• North America (Therapeutics, GBS Variant, Route of Administration, Distribution Channel, Patient Age Group, End User)
  • US
  • Canada
• Europe (Therapeutics, GBS Variant, Route of Administration, Distribution Channel, Patient Age Group, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutics, GBS Variant, Route of Administration, Distribution Channel, Patient Age Group, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutics, GBS Variant, Route of Administration, Distribution Channel, Patient Age Group, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutics, GBS Variant, Route of Administration, Distribution Channel, Patient Age Group, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• CSL Behring LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion Biopharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Argenx SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Annexon Biosciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hansa Medical AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akari Therapeutics PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals Inc. (AstraZeneca)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Healthcare Limited (Zydus)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sarepta Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations